Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial updating efficacy and safety of sintilimab plus ICE versus ICE in patients with classic Hodgkin's lymphoma after failure of first-line chemotherap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classic Hodgkin Lymphoma

Drugs mentioned

• ICE regimen (cyclophosphamide, ifosfamide, etoposide)
• Sintilimab (sintilimab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Classic Hodgkin's Lymphoma | Phase 3 | Status: UNKNOWN